Brokerage Firm Rating Update on Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY) : 5 brokerage houses believe that Bristol-Myers Squibb Company (BMY) is a Strong Buy at current levels. 10 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Bristol-Myers Squibb Company (BMY). Zacks Investment Research suggests a Hold with a rank of 3. 2 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 17 Wall Street Analysts endorse the stock as a Hold with a rating of 2.65.

Bristol-Myers Squibb Company (BMY) : The highest short term price target forecast on Bristol-Myers Squibb Company (BMY) is $100 and the lowest target price is $48. A total of 13 equity analysts are currently covering the company. The average price of all the analysts is $68.39 with a standard deviation of $12.94.


Company shares have received an average consensus rating of Hold for the current week Also, UBS maintains its rating on Bristol-Myers Squibb Company (NYSE:BMY). The global brokerage major lowers the current price target from $80 per share to $70 per share. Analysts at the UBS have a current rating of Buy on the shares. The rating by the firm was issued on August 19, 2016.

Bristol-Myers Squibb Company (NYSE:BMY): stock was range-bound between the intraday low of $56.42 and the intraday high of $57.45 after having opened at $57.02 on Wednesdays session. The stock finally closed in the red at $57.02, a loss of -0.68%. The stock remained in the red for the whole trading day. The total traded volume was 11,719,312 shares. The stock failed to cross $57.45 in Wednesdays trading. The stocks closing price on Thursday was $56.96.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *